These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 27043124

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
    Suzuki H, Hibino H, Inoue Y, Takaya A.
    Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK, Margolese HC.
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract] [Full Text] [Related]

  • 7. Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study.
    Kane JM, Correll CU, Delva N, Gopal S, Savitz A, Mathews M.
    J Clin Psychopharmacol; 2019 Feb; 39(2):180-182. PubMed ID: 30811377
    [No Abstract] [Full Text] [Related]

  • 8. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS, Kim SN, Han J, Lee SI, Chang JS, Choi JS, Lee HJ, Cho SJ, Jun TY, Lee SH, Han C, Lee KU, Lee KK, Lee E.
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in Japan.
    Misawa F, Fujii Y, Takeuchi H.
    J Clin Psychopharmacol; 2015 Nov; 41(2):206-207. PubMed ID: 33538535
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Paliperidone palmitate use in pregnancy in a woman with schizophrenia.
    Özdemir AK, Pak ŞC, Canan F, Geçici Ö, Kuloğlu M, Gücer MK.
    Arch Womens Ment Health; 2015 Oct; 18(5):739-40. PubMed ID: 25599999
    [Abstract] [Full Text] [Related]

  • 18. Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report.
    Yamashita T, Fujii Y, Misawa F.
    J Clin Psychopharmacol; 2013 Feb; 33(1):127-9. PubMed ID: 23288234
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.